LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.3 EUR | +1.93% |
|
+6.10% | +40.03% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,351 | 2,099 | 4,138 | 1,925 | 3,213 | 4,368 | - | - |
| Enterprise Value (EV) 1 | 1,369 | 2,121 | 4,112 | 1,872 | 3,251 | 4,330 | 4,221 | 4,062 |
| P/E ratio | 34.4 x | 34.5 x | 26.7 x | 9.67 x | 18.8 x | 25.5 x | 21.9 x | 16.6 x |
| Yield | 0.72% | 1.01% | 1.29% | 3.59% | 1.83% | 1.33% | 1.53% | 1.92% |
| Capitalization / Revenue | 3.54 x | 5 x | 6.38 x | 2.35 x | 3.87 x | 5.3 x | 4.85 x | 4.18 x |
| EV / Revenue | 3.59 x | 5.05 x | 6.34 x | 2.29 x | 3.92 x | 5.25 x | 4.69 x | 3.88 x |
| EV / EBITDA | 22.5 x | 22.5 x | 20.3 x | 6.72 x | 13.3 x | 17.8 x | 14.8 x | 11 x |
| EV / FCF | -39.2 x | 281 x | 37.9 x | 10.1 x | 54.3 x | 27.8 x | 25.9 x | 18.9 x |
| FCF Yield | -2.55% | 0.36% | 2.64% | 9.95% | 1.84% | 3.6% | 3.86% | 5.3% |
| Price to Book | 4.19 x | 5.62 x | 8.59 x | 3.71 x | - | 6.92 x | 5.61 x | 4.46 x |
| Nbr of stocks (in thousands) | 55,382 | 55,393 | 56,069 | 53,375 | 53,370 | 51,820 | - | - |
| Reference price 2 | 24.40 | 37.90 | 73.80 | 36.06 | 60.20 | 84.30 | 84.30 | 84.30 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 2/21/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 381.3 | 420 | 648.7 | 817.7 | 829.5 | 824.4 | 900 | 1,046 |
| EBITDA 1 | 60.86 | 94.33 | 202.9 | 278.7 | 244.5 | 242.9 | 285.5 | 368.6 |
| EBIT 1 | 42.65 | 74.74 | 181.5 | 255.8 | 220.1 | 217.1 | 258 | 339.3 |
| Operating Margin | 11.18% | 17.8% | 27.98% | 31.29% | 26.53% | 26.34% | 28.67% | 32.43% |
| Earnings before Tax (EBT) 1 | 41.88 | 72.58 | 182.6 | 258 | 220.4 | 213.2 | 251 | 326.4 |
| Net income 1 | 39.27 | 61.06 | 153.1 | 199.7 | 170.3 | 170.7 | 203.6 | 269.7 |
| Net margin | 10.3% | 14.54% | 23.6% | 24.42% | 20.53% | 20.71% | 22.62% | 25.77% |
| EPS 2 | 0.7100 | 1.100 | 2.760 | 3.730 | 3.200 | 3.311 | 3.850 | 5.093 |
| Free Cash Flow 1 | -34.94 | 7.539 | 108.5 | 186.2 | 59.9 | 155.7 | 163 | 215.1 |
| FCF margin | -9.16% | 1.8% | 16.73% | 22.77% | 7.22% | 18.89% | 18.11% | 20.56% |
| FCF Conversion (EBITDA) | - | 7.99% | 53.49% | 66.81% | 24.5% | 64.11% | 57.08% | 58.37% |
| FCF Conversion (Net income) | - | 12.35% | 70.88% | 93.26% | 35.17% | 91.2% | 80.03% | 79.78% |
| Dividend per Share 2 | 0.1751 | 0.3812 | 0.9556 | 1.294 | 1.104 | 1.121 | 1.289 | 1.622 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 2/21/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 191.1 | 290 | 173.5 | 185.2 | 205.6 | 174.8 | 380.4 | 195.1 | 242.2 | 201.6 | 179.2 | 380.8 | 214 | 234.8 | 153.3 |
| EBITDA 1 | 42.41 | 74 | 65.5 | 63.35 | 74.3 | 41.5 | 115.8 | 58.1 | 104.8 | 66.5 | 30.6 | 97.1 | 74.1 | 73.3 | 26.25 |
| EBIT 1 | 32.89 | 63.24 | 60.05 | 58.2 | 68.71 | 35.65 | 104.4 | 52.47 | 99.02 | 60.7 | 24.51 | 85.21 | 68.2 | 66.7 | 20.57 |
| Operating Margin | 17.21% | 21.8% | 34.62% | 31.43% | 33.42% | 20.39% | 27.43% | 26.89% | 40.88% | 30.11% | 13.67% | 22.37% | 31.86% | 28.41% | 13.42% |
| Earnings before Tax (EBT) 1 | - | - | 60.44 | 58.28 | 68.93 | - | - | - | - | 61.2 | - | - | - | - | 19.8 |
| Net income 1 | 29.59 | 51.02 | 47.92 | 54.14 | 53.05 | 27.57 | 80.62 | 40.88 | 78.16 | 47.5 | 19.1 | 66.6 | 52.22 | 51.48 | 11.93 |
| Net margin | 15.48% | 17.59% | 27.62% | 29.24% | 25.8% | 15.77% | 21.19% | 20.95% | 32.27% | 23.56% | 10.66% | 17.49% | 24.4% | 21.93% | 7.79% |
| EPS | - | - | - | 0.9800 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/27/20 | 7/28/21 | 11/3/21 | 2/23/22 | 5/11/22 | 7/27/22 | 7/27/22 | 11/4/22 | 2/21/23 | 5/10/23 | 7/26/23 | 7/26/23 | 11/8/23 | 2/27/24 | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 17.4 | 21.3 | - | - | 38.6 | - | - | - |
| Net Cash position 1 | - | - | 25.9 | 52.8 | - | 38.2 | 147 | 306 |
| Leverage (Debt/EBITDA) | 0.2855 x | 0.2256 x | - | - | 0.1579 x | - | - | - |
| Free Cash Flow 1 | -34.9 | 7.54 | 109 | 186 | 59.9 | 156 | 163 | 215 |
| ROE (net income / shareholders' equity) | 12.9% | 17.5% | 36.2% | 40.3% | 32.2% | 29% | 28.3% | 30.1% |
| ROA (Net income/ Total Assets) | - | - | 23.4% | 24.8% | 21.3% | 19.6% | 21% | 24.6% |
| Assets 1 | - | - | 653.6 | 805.7 | 799.7 | 871.1 | 969.7 | 1,096 |
| Book Value Per Share 2 | 5.820 | 6.750 | 8.590 | 9.730 | - | 12.20 | 15.00 | 18.90 |
| Cash Flow per Share | -0.1600 | 0.8500 | 2.700 | 4.440 | - | - | - | - |
| Capex 1 | 25.9 | 39.3 | 40.9 | 51.4 | 55.2 | 48.9 | 43.7 | 36.8 |
| Capex / Sales | 6.79% | 9.37% | 6.31% | 6.28% | 6.65% | 5.93% | 4.86% | 3.52% |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 2/21/23 | 2/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
84.3
EUR
Average target price
85.12
EUR
Spread / Average Target
+0.98%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.03% | 4.59B | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- ROVI Stock
- Financials Laboratorios Farmaceuticos Rovi, S.A.
